These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17722195)

  • 61. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
    O'Connor AB; Noyes K; Holloway RG
    J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An alternative phase II/III design for continuous endpoints.
    Huang WS; Liu JP; Hsiao CF
    Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A review of phase 2-3 clinical trial designs.
    Thall PF
    Lifetime Data Anal; 2008 Mar; 14(1):37-53. PubMed ID: 17763973
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
    Baek I; Zhu W; Wu X; Wong WK
    J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Translation of innovative designs into phase I trials.
    Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
    J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia.
    Jensen MP; Hsu PH; Vanhove GF
    Pain Med; 2012 Aug; 13(8):1059-66. PubMed ID: 22757655
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
    Biswas A; Bhattacharya R
    J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Response-Adaptive Allocation for Circular Data.
    Biswas A; Dutta S; Laha AK; Bakshi PK
    J Biopharm Stat; 2015; 25(4):830-42. PubMed ID: 24919034
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A response adaptive design for ordinal categorical responses.
    Biswas A; Bhattacharya R; Das S
    J Biopharm Stat; 2018; 28(6):1169-1181. PubMed ID: 29504826
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adaptive enrichment designs for clinical trials.
    Simon N; Simon R
    Biostatistics; 2013 Sep; 14(4):613-25. PubMed ID: 23525452
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Design of clinical trials involving multiple hypothesis tests with a common control.
    Schou IM; Marschner IC
    Biom J; 2017 Jul; 59(4):636-657. PubMed ID: 27704593
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimal designs for testing hypothesis in multiarm clinical trials.
    Baldi Antognini A; Novelli M; Zagoraiou M
    Stat Methods Med Res; 2019; 28(10-11):3242-3259. PubMed ID: 30232928
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adaptive Design for Staggered-Start Clinical Trial.
    Yuan A; Li Q; Xiong M; Tan MT
    Int J Biostat; 2016 Nov; 12(2):. PubMed ID: 26656800
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adaptive response-dependent two-phase designs: Some results on robustness and efficiency.
    Yang C; Diao L; Cook RJ
    Stat Med; 2022 Sep; 41(22):4403-4425. PubMed ID: 35799345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimal and ethical designs for hypothesis testing in multi-arm exponential trials.
    Frieri R; Zagoraiou M
    Stat Med; 2021 May; 40(11):2578-2603. PubMed ID: 33687086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measures.
    Kasianova K; Kelbert M; Mozgunov P
    Comput Stat Data Anal; 2021 Jun; 158():107187. PubMed ID: 34083846
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and Ethics.
    Hu J; Zhu H; Hu F
    J Am Stat Assoc; 2015 Apr; 110(509):357-367. PubMed ID: 26120220
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multi-arm covariate adjusted response adaptive designs for ordinal outcome clinical trials.
    Das S; Bhattacharya R; Biswas A
    Stat Methods Med Res; 2023 Jan; 32(1):88-99. PubMed ID: 36266972
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimal designs in stability studies.
    Hedayat AS; Yan X; Lin L
    J Biopharm Stat; 2006; 16(1):35-59. PubMed ID: 16440836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.